ClinicalTrials.gg
RecruitingNCT06321575GREATUpdated Aug 27, 2026

The Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial)

An interventional study of Golazo® Peripheral Atherectomy System (Golazo® Peripheral AS) in Peripheral Arterial Disease, sponsored by Nipro Vascular Innovations Americas, Inc. Recruiting at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by Nipro Vascular Innovations Americas, Inc · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
159
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 479 studies in Peripheral Arterial Disease with a site in United States — 82 open to participants now, 101 under way, 10 of them phase 3. Peripheral Arterial Disease · United States.

Planned enrollment
97th of 373
159 · median 64
Started
2024
with 20 others
No phase
217 of 479
40 open now
Primary completion
2026-11
later than 26 of 100 live
Registered
431st of 479
by date

Among the 479 studies in Peripheral Arterial Disease with a site in United States, this one is the 97th largest by planned enrollment of the 373 interventional ones that give a count, is one of 21 that started in 2024, is one of 217 with no phase, reaches primary completion later than 26 of the 100 other live ones, and was the 431st registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

82 of the 479 studies in Peripheral Arterial Disease with a site in United States are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 479 studies in Peripheral Arterial Disease with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to establish reasonable assurance of safety and effectiveness of the Golazo® Peripheral Atherectomy System when used as indicated in 159 subjects with symptomatic infrainguinal peripheral arterial disease (PAD) in up to 20 investigational sites in the U.S.

Read the detailed description

The investigation is a prospective, multicenter, non-randomized, single-arm, open-label pivotal clinical study. Subjects will undergo atherectomy treatment with the Golazo® Peripheral Atherectomy System and will then be followed 6-months post-procedure.

03

Conditions studied

  • Peripheral Arterial Disease

Keywords

  • Symptomatic Infrainguinal Peripheral Arterial Disease
  • Endovascular Intervention
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

General inclusion criteria:

  1. Age ≥18 years
  2. Candidate for atherectomy of the peripheral vasculature in the lower limbs
  3. >1 year in the opinion of the investigator
  4. Resting ankle brachial index (ABI) ≤0.90, or ≤0.75 after exercise. Subjects with non-compressible arteries shall have a toe brachial index (TBI) assessment.
  5. Target limb Rutherford clinical classification category 3 to 5
  6. Suitable candidate for angiography and endovascular intervention in the opinion of the investigator
  7. Willing and able to comply with the protocol-specified procedures and assessments
  8. granted

    Angiographic inclusion criteria:

  9. Target lesion(s) defined as stenosis ≥70% by angiographic visual estimation
  10. Total treated lesion length ≤20 cm by angiographic visual estimation
  11. Target reference vessel diameter (RVD) ≥2.0 mm and ≤4.5 mm by angiographic visual estimation
  12. Target limb will have a minimum of one patent (less than 50% stenosis) below the knee (BTK) vessel crossing the ankle, distal to any target lesion, providing perfusion to the foot at baseline

General exclusion criteria:

  1. Active infection in the target limb
  2. History of an endovascular procedure or open vascular surgery on the target limb within the last 30 days
  3. Planned surgical or interventional procedure within 30 days after the index procedure
  4. Lesion in the contralateral limb requiring intervention during the index procedure or within next 30 days
  5. Critical limb ischemia (CLI) with Rutherford clinical classification category 6
  6. Significant acute or chronic kidney disease with a \<30 and/or requiring dialysis
  7. Acute myocardial infarction (non-ST-elevation myocardial infarction or ST-segment elevation myocardial infarction) or other uncontrolled comorbidity in the opinion of the investigator
  8. Myocardial infarction (MI) or stroke within two months of baseline evaluation
  9. Pregnant or lactating
  10. Subject is participating in another clinical investigation of a device, drug, or procedure that has not completed the study treatment or that clinically interferes with the endpoints of this study (post-approval registries are allowed as long as the investigator determines there is no clinical interference with study endpoints)
  11. to antiplatelet, anticoagulant, or thrombolytic therapy
  12. Uncorrectable bleeding diathesis, dysfunction, thrombocytopenia with platelet count \<125,000/microliter, known coagulopathy, or (INR) >1.5
  13. Known allergy to contrast agents or medications used to perform endovascular intervention that cannot be adequately medicated
  14. History of heparin-induced thrombocytopenia (HIT)
  15. Any thrombolytic therapy within two weeks of enrollment
  16. Target lesion(s) within a native vessel graft or synthetic graft
  17. Significant stenosis or occlusion of inflow not successfully treated before the index procedure
  18. Any evidence or history of intracranial or gastrointestinal bleeding or intracranial aneurysm
  19. Vulnerable subject populations (e.g., incarcerated or cognitively challenged adults)
  20. One or more of the following complications of the foot:

    1. Osteomyelitis that extends to the metatarsal bones.
    2. Gangrene involving the plantar skin of the forefoot, midfoot or heel
    3. Deep ulcer or large shallow ulcer (>3cm) involving the plantar skin of the forefoot, midfoot, or heel
    4. Any heel ulcer with/without calcaneal involvement
    5. Any wound with calcaneal bone involvement
    6. Wounds that are deemed to be neuropathic or non-ischemic in nature
    7. Wounds that require flap coverage or complete wound management for large soft tissue defect
  21. Congestive heart failure with a functional classification of III or higher

    Angiographic exclusion criteria:

  22. More than 2 lesions to be treated with the device; lesions located within 3 mm may be considered a single tandem lesion
  23. Clinical/angiographic complication (other than non-flow limiting dissections) attributed to a currently marketed device prior to introduction of the investigational device
  24. In-stent restenosis within the target lesion(s)
  25. Potentially unstable or flow-limiting dissection, type C or greater
  26. Clinical/angiographic evidence of distal embolization
  27. Inability to cross the proximal lesion vessel lumen with a guidewire (not subintimal)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
159 participants (estimated)

Study arms

  • Experimental
    Golazo® Peripheral Atherectomy System

    Treatment atherectomy of the peripheral vasculature with the Golazo® Peripheral Atherectomy System.

    Device: Golazo® Peripheral Atherectomy System (Golazo® Peripheral AS)

Interventions

  • DeviceGolazo® Peripheral Atherectomy System (Golazo® Peripheral AS)

    Golazo® Peripheral AS is a sterile, single-use percutaneous device that has two main components: 1) the Golazo® Accustrike atherectomy catheter, and 2) the Golazo® motorized drive unit (MDU) and is intended for use in atherectomy of the peripheral vasculature.

06

What researchers measure

Primary outcomes

  1. Freedom from major adverse events (MAE)

    MAE is defined as: * Clinically-driven target lesion revascularization (CD-TLR) * Cardiovascular-related deaths * Unplanned major target limb amputation (above the ankle) * Perforations or dissections grade C or greater in the target vessel that require intervention * Symptomatic distal emboli requiring intervention * Pseudoaneurysm requiring intervention

    Time frame: Index procedure through 30-day follow-up

  2. Technical success

    Defined as the percent of target lesions that have a residual diameter stenosis ≤50% after atherectomy with the Golazo Peripheral AS and prior to adjunctive therapy

    Time frame: During surgery/procedure

Secondary outcomes

  1. Change in % stenosis in target lesion after treatment with Golazo Peripheral AS

    Determined after atherectomy and prior to other adjunctive therapies

    Time frame: During surgery/procedure

  2. Procedural Success Rate

    Defined as the proportion of the target lesion in which the final stenosis is ≤30% after treatment with atherectomy and any other adjunctive therapy

    Time frame: End of surgery/procedure

  3. Clinical Success Rate

    Defined as the proportion of subjects who have procedural success in all target lesions with at least one grade of improvement in the Rutherford clinical classification

    Time frame: 30-day and 6-month follow-up

  4. Rates of all adverse events classified as MAEs

    As adjudicated by the CEC and presented by seriousness and causality (procedure and device relatedness)

    Time frame: 30-day and 6-month follow-up

  5. Incidence of minor target limb amputation

    As adjudicated by the CEC

    Time frame: 30-day and 6-month follow-up

  6. Incidence of myocardial infarction

    As adjudicated by the CEC

    Time frame: 30-day and 6-month follow-up

  7. Incidence of target vessel revascularization (TVR) in the target limb

    As adjudicated by the CEC

    Time frame: 30-day and 6-month follow-up

  8. Incidence of angiographic procedural distal embolization in the target limb

    As reported by the angiographic core laboratory

    Time frame: During surgery/procedure

  9. Time to primary patency of the target lesion(s)

    Primary patency is the interval from the time of the index procedure until the time of any intervention designed to maintain or reestablish patency of the target vessels, the time significant stenosis or total occlusion is confirmed, or the time of measurement of patency. Determined by duplex ultrasound/doppler (DUS) or angiography.

    Time frame: 6 months

  10. Time to assisted primary patency of the target lesion(s)

    Assisted primary patency is the interval from the time of the index procedure until the time significant stenosis is confirmed, including interventions designed to maintain patency of a vessel with significant stenosis, the time total occlusion is confirmed, or the time of measurement of patency. Determined by duplex ultrasound/doppler (DUS) or angiography.

    Time frame: 6 months

  11. Time to secondary patency of the target lesion(s)

    Secondary patency is the interval from the time of the index procedure until the time total occlusion is confirmed in a target vessel, including interventions designed to reestablish patency in a total occluded vessel, or the time of measurement of patency. Determined by duplex ultrasound/doppler (DUS) or angiography.

    Time frame: 6 months

07

Study locations

17 of 20 sites recruiting
  • HonorHealth Scottsdale Osborn Medical Center
    Scottsdale, Arizona 85251, United States
    Withdrawn

    Not enrolling at this site.

  • Pulse Cardiovascular Institute
    Scottsdale, Arizona 85251, United States
    Recruiting
    • Anita Ramaiah, MD · Contact480-600-0600
    • Venkatesh Ramaiah, MD · Principal investigator
  • Merced Vascular
    Merced, California 95340, United States
    Recruiting
    • Mani Nallasivan, MD · Principal investigator
  • Palm Vascular Center
    Fort Lauderdale, Florida 33312, United States
    Recruiting
  • First Coast Cardiovascular Institute
    Jacksonville, Florida 32256, United States
    Recruiting
  • Radiology and Imaging Specialists of Lakeland
    Lakeland, Florida 33801, United States
    Completed

    Not enrolling at this site.

  • Amavita Research Services
    Miami, Florida 33137, United States
    Recruiting
  • Cardiovascular Consultants of South Georgia
    Thomasville, Georgia 31792, United States
    Completed

    Not enrolling at this site.

  • Pacific Vascular Institute
    ‘Aiea, Hawaii 96701, United States
    Recruiting
  • Baton Rouge General Hospital
    Baton Rouge, Louisiana 70809, United States
    Recruiting
    • Jamie Mooney · Contact225-237-1673
    • Mary Hamilton · Contact225-237-1673
    • Joseph Griffin, MD · Principal investigator
  • Cardiovascular Institute of the South - Houma
    Houma, Louisiana 70360, United States
    Recruiting
  • Cardiovascular Institute of the South - Lafayette
    Lafayette, Louisiana 70506, United States
    Recruiting
  • Vascular Breakthroughs
    Plymouth, Massachusetts 02360, United States
    Recruiting
    • Elizabeth Gagne · Contact203-548-7860
    • Maria Myslinski · Contact203-548-7860
    • Scott James, DO · Principal investigator
  • Advanced Heart and Vascular Institute
    Flemington, New Jersey 08822, United States
    Recruiting
    • Alexis Bellafiore · Contact908-237-3405
    • Erin Squindo · Contact908-237-3405
    • Andrey Espinoza, MD · Principal investigator
  • Spartanburg Regional Medical Center
    Spartanburg, South Carolina 29303, United States
    Recruiting
    • Darla Howard, RN · Contactdhoward@srhs.com · 864-560-1042
    • Shannon Stancil · Contactsstancil@srhs.com · 864-560-1036
    • Brian Brown, MD · Principal investigator
  • Tennessee Center for Clinical Trials
    Tullahoma, Tennessee 37388, United States
    Recruiting
    • Dinesh Gupta, MD · Principal investigator
  • Nextstage Clinical Research - Beaumont
    Beaumont, Texas 77702, United States
    Recruiting
    • Jorge Hernandez, MD · Principal investigator
  • Hope Vascular & Podiatry
    Houston, Texas 77054, United States
    Recruiting
    • Miguel Montero-Backer · Contactmmontero@hcic.io
    • Stuart Baugher · Contactsbaugher@hcic.io · (346) 541-6421
    • Miguel Montero-Baker, MD · Principal investigator
  • Nextstage Clinical Research - Waco
    Waco, Texas 76712, United States
    Recruiting
    • Donald S Cross, MD · Principal investigator
  • Bellin Health
    Green Bay, Wisconsin 54301, United States
    Recruiting
    • Katherine Guilliams · Contact920-617-2060
    • Christen Piaskowski · Contact920-617-2060
    • Jason Ricci, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Nov 2026, 29 months after the start.

Of 125 industry-sponsored interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 45. This study's planned 29 months is close to that.

Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2024
First posted
Mar 20, 2024
StartActual
Jun 20, 2024
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06321575
Lead sponsor
Nipro Vascular Innovations Americas, Inc
Collaborators
Bright Research, Inc., Yale Cardiovascular Research Group
Responsible party
Sponsor
First posted
Mar 20, 2024
Start date
Jun 20, 2024
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Aug 27, 2026

Study contacts

Gene Reu
Contact
Gene.Reu@nipromed.com
858-945-0007
Jessi Maumee
Contact
jessi.maumee@brightresearch.com
612-345-4544
Matthew Finn, MD
principal investigator · Cardiovascular Institute of the South
Craig Walker, MD
principal investigator · Cardiovascular Institute of the South

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion